RET and non-small cell lung carcinoma: A recent phase I/II study (LIBRETTO-001, NCT03157128) investigated the efficacy and toxicity of selpercatinib separately in two different cohort studies in previously treated and treatment-naïve patients with advanced RET fusion-positive NSCLC [121].